BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

737 related articles for article (PubMed ID: 28483402)

  • 1. Doxycycline for outpatient-treated acute exacerbations of COPD: a randomised double-blind placebo-controlled trial.
    van Velzen P; Ter Riet G; Bresser P; Baars JJ; van den Berg BTJ; van den Berg JWK; Brinkman P; Dagelet JWF; Daniels JMA; Groeneveld-Tjiong DRGL; Jonkers RE; van Kan C; Krouwels FH; Pool K; Rudolphus A; Sterk PJ; Prins JM
    Lancet Respir Med; 2017 Jun; 5(6):492-499. PubMed ID: 28483402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blood eosinophil-guided oral prednisolone for COPD exacerbations in primary care in the UK (STARR2): a non-inferiority, multicentre, double-blind, placebo-controlled, randomised controlled trial.
    Ramakrishnan S; Jeffers H; Langford-Wiley B; Davies J; Thulborn SJ; Mahdi M; A'Court C; Binnian I; Bright S; Cartwright S; Glover V; Law A; Fox R; Jones A; Davies C; Copping D; Russell RE; Bafadhel M
    Lancet Respir Med; 2024 Jan; 12(1):67-77. PubMed ID: 37924830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-dose oral theophylline combined with inhaled corticosteroids for people with chronic obstructive pulmonary disease and high risk of exacerbations: a RCT.
    Devereux G; Cotton S; Fielding S; McMeekin N; Barnes PJ; Briggs A; Burns G; Chaudhuri R; Chrystyn H; Davies L; Soyza A; Gompertz S; Haughney J; Innes K; Kaniewska J; Lee A; Morice A; Norrie J; Sullivan A; Wilson A; Price D
    Health Technol Assess; 2019 Jul; 23(37):1-146. PubMed ID: 31343402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial.
    Uzun S; Djamin RS; Kluytmans JA; Mulder PG; van't Veer NE; Ermens AA; Pelle AJ; Hoogsteden HC; Aerts JG; van der Eerden MM
    Lancet Respir Med; 2014 May; 2(5):361-8. PubMed ID: 24746000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Doxycycline Added to Prednisolone in Outpatient-Treated Acute Exacerbations of COPD: A Cost-Effectiveness Analysis Alongside a Randomised Controlled Trial.
    Finch AP; van Velzen P; Ter Riet G; Sterk PJ; Prins JM; Bosmans JE
    Pharmacoeconomics; 2019 May; 37(5):689-699. PubMed ID: 30565022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial.
    Zheng JP; Wen FQ; Bai CX; Wan HY; Kang J; Chen P; Yao WZ; Ma LJ; Li X; Raiteri L; Sardina M; Gao Y; Wang BS; Zhong NS;
    Lancet Respir Med; 2014 Mar; 2(3):187-94. PubMed ID: 24621680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of age on real-life effects of doxycycline for acute exacerbations among COPD outpatients: a population-based cohort study.
    Wang Y; Bos JH; Boezen HM; Alffenaar JC; van Boven JFM; Schuiling-Veninga CCM; Wilffert B; Hak E
    BMJ Open Respir Res; 2020 Feb; 7(1):. PubMed ID: 32075781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial.
    Martinez FJ; Calverley PM; Goehring UM; Brose M; Fabbri LM; Rabe KF
    Lancet; 2015 Mar; 385(9971):857-66. PubMed ID: 25684586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial.
    Singh D; Papi A; Corradi M; Pavlišová I; Montagna I; Francisco C; Cohuet G; Vezzoli S; Scuri M; Vestbo J
    Lancet; 2016 Sep; 388(10048):963-73. PubMed ID: 27598678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction of corticosteroid use in outpatient treatment of exacerbated COPD - Study protocol for a randomized, double-blind, non-inferiority study, (The RECUT-trial).
    Urwyler P; Boesing M; Abig K; Cattaneo M; Dieterle T; Zeller A; Bachler H; Markun S; Senn O; Merlo C; Essig S; Ullmer E; Rutishauser J; Schuurmans MM; Leuppi JD
    Trials; 2019 Dec; 20(1):727. PubMed ID: 31842993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial.
    Decramer M; Celli B; Kesten S; Lystig T; Mehra S; Tashkin DP;
    Lancet; 2009 Oct; 374(9696):1171-8. PubMed ID: 19716598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of low-dose oral theophylline as an adjunct to inhaled corticosteroids in preventing exacerbations of chronic obstructive pulmonary disease: study protocol for a randomised controlled trial.
    Devereux G; Cotton S; Barnes P; Briggs A; Burns G; Chaudhuri R; Chrystyn H; Davies L; De Soyza A; Fielding S; Gompertz S; Haughney J; Lee AJ; McCormack K; McPherson G; Morice A; Norrie J; Sullivan A; Wilson A; Price D
    Trials; 2015 Jun; 16():267. PubMed ID: 26058585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A double-blind, randomised, placebo-controlled study of roxithromycin and doxycycline combination, roxithromycin alone, or matching placebo for 12 weeks in adults with frequent exacerbations of chronic obstructive pulmonary disease.
    Shafuddin E; Mills GD; Holmes MD; Poole PJ; Mullins PR; Black PN
    J Negat Results Biomed; 2015 Sep; 14():15. PubMed ID: 26346300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial.
    Chupp GL; Bradford ES; Albers FC; Bratton DJ; Wang-Jairaj J; Nelsen LM; Trevor JL; Magnan A; Ten Brinke A
    Lancet Respir Med; 2017 May; 5(5):390-400. PubMed ID: 28395936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease.
    Walters JA; Tan DJ; White CJ; Wood-Baker R
    Cochrane Database Syst Rev; 2014 Dec; (12):CD006897. PubMed ID: 25491891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study.
    Brightling CE; Bleecker ER; Panettieri RA; Bafadhel M; She D; Ward CK; Xu X; Birrell C; van der Merwe R
    Lancet Respir Med; 2014 Nov; 2(11):891-901. PubMed ID: 25208464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term azithromycin for Indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised controlled trial.
    Valery PC; Morris PS; Byrnes CA; Grimwood K; Torzillo PJ; Bauert PA; Masters IB; Diaz A; McCallum GB; Mobberley C; Tjhung I; Hare KM; Ware RS; Chang AB
    Lancet Respir Med; 2013 Oct; 1(8):610-620. PubMed ID: 24461664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Theophylline as Adjunct to Inhaled Corticosteroids on Exacerbations in Patients With COPD: A Randomized Clinical Trial.
    Devereux G; Cotton S; Fielding S; McMeekin N; Barnes PJ; Briggs A; Burns G; Chaudhuri R; Chrystyn H; Davies L; De Soyza A; Gompertz S; Haughney J; Innes K; Kaniewska J; Lee A; Morice A; Norrie J; Sullivan A; Wilson A; Price D
    JAMA; 2018 Oct; 320(15):1548-1559. PubMed ID: 30326124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial.
    Leuppi JD; Schuetz P; Bingisser R; Bodmer M; Briel M; Drescher T; Duerring U; Henzen C; Leibbrandt Y; Maier S; Miedinger D; Müller B; Scherr A; Schindler C; Stoeckli R; Viatte S; von Garnier C; Tamm M; Rutishauser J
    JAMA; 2013 Jun; 309(21):2223-31. PubMed ID: 23695200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials.
    Bernstein JA; Virchow JC; Murphy K; Maspero JF; Jacobs J; Adir Y; Humbert M; Castro M; Marsteller DA; McElhattan J; Hickey L; Garin M; Vanlandingham R; Brusselle G
    Lancet Respir Med; 2020 May; 8(5):461-474. PubMed ID: 32066536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.